Benchmark Research | Sacramento, CA

Research site

(Unclaimed)

Location

4345 Arden Way, Sacramento, California, United States of America

Site insights

Top conditions

Top treatments

Ritonavir

EYE201

EYE103

Peramivir

Fluticasone Proprionate

Ranibizumab

Lubiprostone

Ulipristal Acetate

Ciprofloxacin

Olopatadine

Parent organization

This site is a part of Benchmark Research

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

5 of 32 total trials

Locations recently updated

A 2-part Study Consisting of a Multiple Ascending Dose Safety Study in Participants With Macular Edema Following Branch Retinal Vein Occlusion and a Dose-finding Safety and Preliminary Efficacy Study in Participants With Either Diabetic Macular Edema or Neovascular Age-related Macular Degeneration

EYE-TIE-201 is a 2-part study to investigate the safety and effectiveness of a new drug being developed called EYE201.All participants in the study w...

Enrolling

BRVO - Branch Retinal Vein Occlusion

Diabetic Macular Edema (DME)

Drug: EYE201

A Study of mRNA-1283 Injection Compared With mRNA-1273 Injection in Participants ≥12 Years of Age to Prevent COVID-19 (NextCOVE)

The purpose of this study (Part 1 and Part 2) is to evaluate the relative vaccine efficacy (rVE), safety, reactogenicity, and immunogenicity of mRNA-...

Active, not recruiting

COVID-19

Biological: mRNA-1283.222

Biological: mRNA-1273.815

A Study of mRNA-based Influenza and SARS-CoV-2 (COVID-19) Multi-component Vaccines in Healthy Adults

The study is divided into 2 parts: Part 1 and Part 2. The purpose of Part 1 of this study is to generate sufficient safety, reactogenicity, and immun...

Active, not recruiting

Influenza

SARS-CoV-2

Biological: Investigational Influenza Vaccine 1

Biological: COVID-19 Vaccine 2

Locations recently updated

A Study to Evaluate the Efficacy and Safety of 2 Doses of EYE103 Compared With Ranibizumab (0.5 mg) in Participants With DME (BRUNELLO)

EYE-RES-102 is a randomized, double masked pivotal study to evaluate the efficacy and safety of 2 dose levels of EYE103 in comparison with the active...

Enrolling

Diabetic Macular Edema (DME)

Drug: EYE103

Drug: Ranibizumab

Study to Evaluate the Efficacy, Immunogenicity, and Safety of RSVpreF in Adults. (RENOIR)

Efficacy Study: This randomized, double-blinded, placebo-controlled Phase 3 study is designed to assess the safety, immunogenicity, and efficacy of a...

Enrolling

Lower Respiratory Tract Illness

Biological: RSVpreF

Biological: Placebo